EMA Authorised: Filgrastim Hexal (filgrastim) — Hexal AG

View source ↗

Summary

EMA authorised Filgrastim Hexal (filgrastim), a biosimilar granulocyte colony-stimulating factor, for neutropenia management in cancer patients and in hematopoi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neutropenia

Drugs mentioned

• Filgrastim HEXAL® (filgrastim)

Snippet

Status: Authorised. Therapeutic area: Hematopoietic Stem Cell Transplantation;Cancer. MAH: Hexal AG. Decision date: 20/03/2025